Lupus Nephritis Treatment Market Report and Forecast 2025-2034
Description
The lupus nephritis treatment market size was valued at USD 1.80 Billion in 2024, driven by the emphasis on preventing kidney failures. The market is expected to grow at a CAGR of 7.50% during the forecast period of 2025-2034, with the values likely to reach USD 3.71 Billion by 2034.
Lupus Nephritis Treatment: Introduction
Lupus is an autoimmune disease wherein the immune system starts attacking the healthy cells of the body. Lupus nephritis is the specific targeting and damage to the kidneys. Proliferative nephritis is the most severe kind of nephritis that may even cause permanent damage to the kidneys. Lupus nephritis treatment includes the administration of corticosteroids, immunosuppressants, blood pressure medications and diuretics. Dietary changes like reduced sodium intake and lesser consumption of protein are also advised as a part of the treatment.
Lupus Nephritis Treatment Market Analysis
Lupus nephritis treatment has observed significant evolution in recent years. B cells play a pivotal role in the pathogenesis of lupus nephritis. Hence, major areas of action in any medication revolve around either B-cell depletion or anti-B-cell activation. Currently, Rituximab is a commonly used medication for lupus nephritis treatment. Numerous medications are also under clinical trials, which are further expected to fuel the lupus nephritis treatment market growth.
Lupus nephritis may lead to chronic kidney failure diseases and is also associated with high blood pressure. Voclosporin (Lupkynis™) has been found safe and effective in treating the disease. It is a structurally modified calcineurin inhibitor, which acts as an immunosuppressant as well as promotes podocyte stability in the kidney. It also led to continuous improvement in proteinuria (presence of protein urine), which is another major symptom of lupus nephritis.
In June 2023, Kyverna Therapeutics, a United States based cell therapy company, received the FDA approval for KYV-101, designed to treat refractory lupus nephritis. The medication works on a novel anti-CD19 chimeric antigen receptor T-cell (CAR T) therapy which depletes B cells, including autoreactive B cells, present in patients with this autoimmune disease. With the advent of new therapies and latest advancements, the lupus nephritis treatment market demand is expected to rise more in the upcoming years.
Lupus Nephritis Treatment Market Segmentation
“Lupus Nephritis Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
The growing convergence of technology into the medical ecosystem has paved the way for artificial intelligence and machine learning enabled diagnosis. The United States, having a robust medical and technical infrastructure, is anticipated to pioneer the lupus nephritis treatment market share in the forecast period. The researchers from University of Houston have also received a USD 3 million grant to offer rapid and precise diagnosis of the disease.
Europe is another major market for lupus nephritis treatment. With a prominent healthcare scenario for the geriatric population, it is home to several leading research and academic institutions working on offering effective treatment options to a wide set of audiences present in the region.
The Asia Pacific region is expected to witness a rapid surge in the lupus nephritis treatment market value, attributed to high investment in building medical infrastructure. There is also an influx of foreign capital, especially from leading medical companies. Government initiatives to spread relevant awareness are also on the rise. Lupus Awareness Month organized every October in Australia is a prime example. This program is aimed at delivering awareness of disease to offer early diagnosis and improve treatment.
Lupus Nephritis Treatment Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Lupus Nephritis Treatment: Introduction
Lupus is an autoimmune disease wherein the immune system starts attacking the healthy cells of the body. Lupus nephritis is the specific targeting and damage to the kidneys. Proliferative nephritis is the most severe kind of nephritis that may even cause permanent damage to the kidneys. Lupus nephritis treatment includes the administration of corticosteroids, immunosuppressants, blood pressure medications and diuretics. Dietary changes like reduced sodium intake and lesser consumption of protein are also advised as a part of the treatment.
Lupus Nephritis Treatment Market Analysis
Lupus nephritis treatment has observed significant evolution in recent years. B cells play a pivotal role in the pathogenesis of lupus nephritis. Hence, major areas of action in any medication revolve around either B-cell depletion or anti-B-cell activation. Currently, Rituximab is a commonly used medication for lupus nephritis treatment. Numerous medications are also under clinical trials, which are further expected to fuel the lupus nephritis treatment market growth.
Lupus nephritis may lead to chronic kidney failure diseases and is also associated with high blood pressure. Voclosporin (Lupkynis™) has been found safe and effective in treating the disease. It is a structurally modified calcineurin inhibitor, which acts as an immunosuppressant as well as promotes podocyte stability in the kidney. It also led to continuous improvement in proteinuria (presence of protein urine), which is another major symptom of lupus nephritis.
In June 2023, Kyverna Therapeutics, a United States based cell therapy company, received the FDA approval for KYV-101, designed to treat refractory lupus nephritis. The medication works on a novel anti-CD19 chimeric antigen receptor T-cell (CAR T) therapy which depletes B cells, including autoreactive B cells, present in patients with this autoimmune disease. With the advent of new therapies and latest advancements, the lupus nephritis treatment market demand is expected to rise more in the upcoming years.
Lupus Nephritis Treatment Market Segmentation
“Lupus Nephritis Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
- NSAIDs
- Corticosteroids
- Immunosuppressants
- Others
- Medication
- Dialysis
- Kidney Transplant
- Oral
- Parenteral
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- Hospitals and Clinics
- Research and Academic Laboratories
- Others
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
The growing convergence of technology into the medical ecosystem has paved the way for artificial intelligence and machine learning enabled diagnosis. The United States, having a robust medical and technical infrastructure, is anticipated to pioneer the lupus nephritis treatment market share in the forecast period. The researchers from University of Houston have also received a USD 3 million grant to offer rapid and precise diagnosis of the disease.
Europe is another major market for lupus nephritis treatment. With a prominent healthcare scenario for the geriatric population, it is home to several leading research and academic institutions working on offering effective treatment options to a wide set of audiences present in the region.
The Asia Pacific region is expected to witness a rapid surge in the lupus nephritis treatment market value, attributed to high investment in building medical infrastructure. There is also an influx of foreign capital, especially from leading medical companies. Government initiatives to spread relevant awareness are also on the rise. Lupus Awareness Month organized every October in Australia is a prime example. This program is aimed at delivering awareness of disease to offer early diagnosis and improve treatment.
Lupus Nephritis Treatment Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- F. Hoffmann-La Roche Ltd
- AstraZeneca
- Aurinia Pharmaceuticals Inc.
- GlaxoSmithKline plc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Vertice Pharma
- Bayer AG
- Sanofi
- Sumitomo Corporation
- LEO Pharma A/S
- Cipla Inc.
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Lupus Nephritis Treatment Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Lupus Nephritis Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Lupus Nephritis Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Lupus Nephritis Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Lupus Nephritis Epidemiology Forecast (2018-2034)
- 5.3.2 France Lupus Nephritis Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Lupus Nephritis Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Lupus Nephritis Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Lupus Nephritis Epidemiology Forecast (2018-2034)
- 5.4 Japan Lupus Nephritis Epidemiology Forecast (2018-2034)
- 6 Lupus Nephritis Treatment Market Overview – 7MM
- 6.1 Lupus Nephritis Treatment Market Historical Value (2018-2024)
- 6.2 Lupus Nephritis Treatment Market Forecast Value (2025-2034)
- 7 Lupus Nephritis Treatment Market Landscape – 7MM
- 7.1 Amyotrophic Lateral Sclerosis: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Lupus Nephritis Treatment Product Landscape
- 7.2.1 Analysis by Drug Class
- 7.2.2 Analysis by Treatment Type
- 7.2.3 Analysis by Route of Administration
- 8 Lupus Nephritis Treatment Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Lupus Nephritis Treatment Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Lupus Nephritis Treatment Market Segmentation – 7MM
- 11.1 Lupus Nephritis Treatment Market by Drug Class
- 11.1.1 Market Overview
- 11.1.2 NSAIDs
- 11.1.3 Corticosteroids
- 11.1.4 Immunosuppressants
- 11.1.5 Others
- 11.2 Lupus Nephritis Treatment Market by Treatment Type
- 11.2.1 Market Overview
- 11.2.2 Medication
- 11.2.3 Dialysis
- 11.2.4 Kidney Transplant
- 11.3 Lupus Nephritis Treatment Market by Route of Administration
- 11.3.1 Market Overview
- 11.3.2 Oral
- 11.3.3 Parenteral
- 11.3.4 Others
- 11.4 Lupus Nephritis Treatment Market by End User
- 11.4.1 Market Overview
- 11.4.2 Hospitals and Clinics
- 11.4.3 Research and Academic Laboratories
- 11.4.4 Others
- 11.5 Lupus Nephritis Treatment Market by Distribution Channels
- 11.5.1 Market Overview
- 11.5.2 Hospital Pharmacy
- 11.5.3 Retail Pharmacy
- 11.5.4 Online Pharmacy
- 11.5.5 Others
- 11.6 Lupus Nephritis Treatment Market by Region
- 11.6.1 Market Overview
- 11.6.2 United States
- 11.6.3 EU-4 and the United Kingdom
- 11.6.3.1 Germany
- 11.6.3.2 France
- 11.6.3.3 Italy
- 11.6.3.4 Spain
- 11.6.3.5 United Kingdom
- 11.6.4 Japan
- 12 United States Lupus Nephritis Treatment Market
- 12.1 Lupus Nephritis Treatment Market Historical Value (2018-2024)
- 12.2 Lupus Nephritis Treatment Market Forecast Value (2025-2034)
- 12.3 Lupus Nephritis Treatment Market by Drug Class
- 12.4 Lupus Nephritis Treatment Market by Treatment Type
- 13 EU-4 and United Kingdom Lupus Nephritis Treatment Market
- 13.1 Lupus Nephritis Treatment Market Historical Value (2018-2024)
- 13.2 Lupus Nephritis Treatment Market Forecast Value (2025-2034)
- 13.3 Germany Lupus Nephritis Treatment Market Overview
- 13.3.1 Lupus Nephritis Treatment Market by Drug Class
- 13.3.2 Lupus Nephritis Treatment Market by Treatment Type
- 13.4 France Lupus Nephritis Treatment Market Overview
- 13.4.1 Lupus Nephritis Treatment Market by Drug Class
- 13.4.2 Lupus Nephritis Treatment Market by Treatment Type
- 13.5 Italy Lupus Nephritis Treatment Market Overview
- 13.5.1 Lupus Nephritis Treatment Market by Drug Class
- 13.5.2 Lupus Nephritis Treatment Market by Treatment Type
- 13.6 Spain Lupus Nephritis Treatment Market Overview
- 13.6.1 Lupus Nephritis Treatment Market by Drug Class
- 13.6.2 Lupus Nephritis Treatment Market by Treatment Type
- 13.7 United Kingdom Lupus Nephritis Treatment Market Overview
- 13.7.1 Lupus Nephritis Treatment Market by Drug Class
- 13.7.2 Lupus Nephritis Treatment Market by Treatment Type
- 14 Japan Lupus Nephritis Treatment Market
- 14.1 Lupus Nephritis Treatment Market Historical Value (2018-2024)
- 14.2 Lupus Nephritis Treatment Market Forecast Value (2025-2034)
- 14.3 Lupus Nephritis Treatment Market by Drug Class
- 14.4 Lupus Nephritis Treatment Market by Treatment Type
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 JAPAN PMDA
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Grants Analysis
- 17.1 Analysis by year
- 17.2 Analysis by Amount Awarded
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Grant Application
- 17.5 Analysis by Funding Institute
- 17.6 Analysis by NIH Departments
- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
- 19.1 Analysis by Funding Instances
- 19.2 Analysis by Type of Funding
- 19.3 Analysis by Funding Amount
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Leading Investors
- 19.6 Analysis by Geography
- 20 Partnerships and Collaborations Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
- 21.1 F. Hoffmann-La Roche Ltd
- 21.1.1 Financial Analysis
- 21.1.2 Product Portfolio
- 21.1.3 Demographic Reach and Achievements
- 21.1.4 Mergers and Acquisitions
- 21.1.5 Certifications
- 21.2 AstraZeneca
- 21.2.1 Financial Analysis
- 21.2.2 Product Portfolio
- 21.2.3 Demographic Reach and Achievements
- 21.2.4 Mergers and Acquisitions
- 21.2.5 Certifications
- 21.3 Aurinia Pharmaceuticals Inc.
- 21.3.1 Financial Analysis
- 21.3.2 Product Portfolio
- 21.3.3 Demographic Reach and Achievements
- 21.3.4 Mergers and Acquisitions
- 21.3.5 Certifications
- 21.4 GlaxoSmithKline plc.
- 21.4.1 Financial Analysis
- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisitions
- 21.4.5 Certifications
- 21.5 Bristol-Myers Squibb Company
- 21.5.1 Financial Analysis
- 21.5.2 Product Portfolio
- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisitions
- 21.5.5 Certifications
- 21.6 Eli Lilly and Company
- 21.6.1 Financial Analysis
- 21.6.2 Product Portfolio
- 21.6.3 Demographic Reach and Achievements
- 21.6.4 Mergers and Acquisitions
- 21.6.5 Certifications
- 21.7 Merck & Co., Inc.
- 21.7.1 Financial Analysis
- 21.7.2 Product Portfolio
- 21.7.3 Demographic Reach and Achievements
- 21.7.4 Mergers and Acquisitions
- 21.7.5 Certifications
- 21.8 Novartis AG
- 21.8.1 Financial Analysis
- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisitions
- 21.8.5 Certifications
- 21.9 Pfizer Inc.
- 21.9.1 Financial Analysis
- 21.9.2 Product Portfolio
- 21.9.3 Demographic Reach and Achievements
- 21.9.4 Mergers and Acquisitions
- 21.9.5 Certifications
- 21.10 Vertice Pharma
- 21.10.1 Financial Analysis
- 21.10.2 Product Portfolio
- 21.10.3 Demographic Reach and Achievements
- 21.10.4 Mergers and Acquisitions
- 21.10.5 Certifications
- 21.11 Bayer AG
- 21.11.1 Financial Analysis
- 21.11.2 Product Portfolio
- 21.11.3 Demographic Reach and Achievements
- 21.11.4 Mergers and Acquisitions
- 21.11.5 Certifications
- 21.12 Sanofi
- 21.12.1 Financial Analysis
- 21.12.2 Product Portfolio
- 21.12.3 Demographic Reach and Achievements
- 21.12.4 Mergers and Acquisitions
- 21.12.5 Certifications
- 21.13 Sumitomo Corporation
- 21.13.1 Financial Analysis
- 21.13.2 Product Portfolio
- 21.13.3 Demographic Reach and Achievements
- 21.13.4 Mergers and Acquisitions
- 21.13.5 Certifications
- 21.14 LEO Pharma A/S
- 21.14.1 Financial Analysis
- 21.14.2 Product Portfolio
- 21.14.3 Demographic Reach and Achievements
- 21.14.4 Mergers and Acquisitions
- 21.14.5 Certifications
- 21.15 Cipla Inc.
- 21.15.1 Financial Analysis
- 21.15.2 Product Portfolio
- 21.15.3 Demographic Reach and Achievements
- 21.15.4 Mergers and Acquisitions
- 21.15.5 Certifications
- 22 Lupus Nephritis Treatment Market- Distribution Model (Additional Insight)
- 22.1 Overview
- 22.2 Potential Distributors
- 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
- 24.1 Very Small Companies
- 24.2 Small Companies
- 24.3 Mid-Sized Companies
- 24.4 Large Companies
- 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
